Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, Messina, Italy.
Dermatol Ther. 2021 Jan;34(1):e14660. doi: 10.1111/dth.14660. Epub 2020 Dec 25.
Psoriasis is a chronic immune-mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life-long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL-23/IL-17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.
银屑病是一种慢性免疫介导性疾病，其特征为皮肤（银屑病）或关节（银屑病关节炎）炎症，或两者兼有，源于特定的辅助性 T 细胞（Th）17 功能失调。目前尚无治愈银屑病的方法，需要进行终身治疗以控制症状。针对批准用于治疗中重度银屑病和银屑病关节炎的最新生物药物，尤其是针对阻断 IL-23/IL-17 轴的药物，研究兴趣很高。我们旨在综述用于治疗银屑病的新型生物药物及其不良反应，重点关注感染风险。
